New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs
Executive Summary
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
You may also be interested in...
Ionis Partners With Metagenomi To Expand Its Genetic Medicines Capabilities
Ionis will pay $80m up front to Metagenomi to access its next-generation gene-editing technology to jointly research new therapies for up to four genetic targets.
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.